Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma

American Journal of Health-System Pharmacy

Volumn 73, Issue 4, 2016, Pages 193-201

  Ivashko, Igor N ^a   Kolesar, Jill M ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; INTERLEUKIN 2; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ACUTE HEPATITIS; ACUTE KIDNEY FAILURE; ADVANCED CANCER; ARTHRALGIA; B LYMPHOCYTE; CANCER SURVIVAL; COLITIS; CONTINUOUS INFUSION; DENDRITIC CELL; DIARRHEA; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; FATIGUE; GENE MUTATION; HEADACHE; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOTHYROIDISM; IMMUNE RESPONSE; IMMUNOREGULATION; KIDNEY FAILURE; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; METASTATIC MELANOMA; MULTICENTER STUDY (TOPIC); MYALGIA; NAUSEA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; REVIEW; SKIN DISEASE; T LYMPHOCYTE; TREATMENT RESPONSE; VOLUME OF DISTRIBUTION AT STEADY-STATE; WEAKNESS; ANTAGONISTS AND INHIBITORS; DISEASE COURSE; IMMUNOTHERAPY; MELANOMA; PATHOLOGY; PROCEDURES; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; MELANOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS;

EID: 84964053744     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp140768     Document Type: Review

References (43)

1. National Cancer Institute. SEER stat fact sheets: Melanoma of the skin. http://seer.cancer.gov/statfacts/html/melan.html (accessed 2015 Oct 5).
2. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: An overview. Oncology. 2009; 23:488-96.
3. Kim CJ, Dessureault S, Gabrilovich D et al. Immunotherapy for melanoma. Cancer Control. 2002; 9:22-30.
4. Durán García E, Santolaya R, Requena T. Treatment of malignant melanoma. Ann Pharmacother. 1999; 33:730-8.
5. Yang AS, Chapman PB. The history and future of chemotherapy for melanoma. Hematol Oncol Clin North Am. 2009; 23:583-97.
6. Ahmann DL, Creagan ET, Hahn RG et al. Complete responses and longterm survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer. 1989; 63:224-7.
7. Rosenberg SA, Yang JC, Topalian S et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2, JAMA. 1994; 271:907-13.
8. Food and Drug Administration. Hematology/oncology (cancer) approvals and safety notifications: 2013-2014 notifications. www.fda. gov/drugs/informationondrugs/approveddrugs/ucm279174.htm (accessed 2014 Sep 5).
9. Food and Drug Administration. Hematology/oncology (cancer) approvals & safety notifications: 2011 notifications. www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm381453.htm (accessed 2014 Sep 5).
10. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): Melanoma, version 3.2015. www.nccn.org/professionals/physician-gls/pdf/melanoma (accessed 2015 Oct 5).
11. Homet B, Ribas A. New drug targets in metastatic melanoma. J Pathol. 2014; 232:134-41.
12. Lovly CM, Shaw AT. Molecular pathways: Resistance to kinase inhibitors and implications for therapeutic strategies. Clin Cancer Res. 2014; 20:2249-56.
13. Kugel CH 3rd, Aplin AE. Adaptive resistance to RAF inhibitors in melanoma. Pigment Cell Melanoma Res. 2014; 27:1032-8.
14. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol. 2001; 1:220-8.
15. Egen JG, Kuhns MS, Allison JP. CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat Immunol. 2002; 3:611-8.
16. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol. 2001; 19:565-94.
17. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol. 2005; 175:7746-54.
18. Hodi FS, O'Day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363:711-23.
19. Food and Drug Administration. Yervoy (ipilimumab): Risk evaluation and mitigation strategy (REMS)-severe immune-mediated adverse reactions. www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm249770.htm (accessed 2014 Sep 5).
20. Food and Drug Administration. Novel new drugs, 2014 summary. www.fda. gov/downloads/Drugs/Development ApprovalProcess/DrugInnovation/UCM430299 (accessed 2015 Jan 16).
21. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol. 2009; 27:591-619.
22. Boussiotis VA, Chatterjee P, Li L. Biochemical signaling of PD-1 on T cells and its functional implications. Cancer J. 2014; 20:265-71.
23. Liang SC, Latchman YE, Buhlmann JE et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol. 2003; 33:2706-16.
24. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002; 2:116-26.
25. Zhong X, Tumang JR, Gao W et al. PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for V(H)11/V(H)12 and phosphatidylcholine binding. Eur J Immunol. 2007; 37:2405-10.
26. Food and Drug Administration. Highlights of prescribing information. Keytruda (pembrolizumab) for injection, for intravenous use. www. accessdata.fda.gov/drugsatfda-docs/label/2014/125514lbl.pdf (accessed 2014 Oct 15).
27. Culver ME, Gatesman ML, Mancl EE, Lowe DK. Ipilimumab: A novel treatment for metastatic melanoma. Ann Pharmacother. 2011; 45:510-9.
28. Blank C, Kuball J, Voelkl S et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006; 119:317-27.
29. Wong RM, Scotland RR, Lau RL et al. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol. 2007; 19:1223-34.
30. Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013; 369:134-44.
31. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45:228-47.
32. Robert C, Ribas A, Wolchok JD et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dosecomparison cohort of a phase 1 trial. Lancet. 2014; 384:1109-17.
33. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366:2443-54.
34. Lexicomp Online. Pembrolizumab: Drug information. http://online.lexi. com/lco/action/doc/retrieve/docid/patch-f/5320082 (accessed 2015 Feb 2).
35. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent antiprogrammed death-1 (NIVOLUMAB) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28:3167-75.
36. Topalian SL, Sznol M, Mcdermott DF et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014; 32:1020-30.
37. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015; 372:320-30.
38. Weber JS, D'Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA4 treatment (CheckMate037): A randomized controlled, open label phase III trial. Lancet Oncol. 2015; 4:375-84.
39. Food and Drug Administration. Highlights of prescribing information. Opdivo (nivolumab) for injection, for intravenous use. www. accessdata.fda.gov/drugsatfda-docs/label/2014/125554lbl (accessed 2015 Jan 10).
40. Lexicomp Online. Nivolumab: Drug information. http://online.lexi.com/lco/action/doc/retrieve/docid/patch-f/5467454-fee (accessed 2015 Feb 2).
41. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015; 372:2521-32.
42. Long GV, Stroyakovskiy D, Gogas H et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014; 371:1877-88.
43. Robert C, Karaszewska B, Schachter J et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015; 372:30-9.